8 / 25
CARÁCTERÍSTICAS DE LAS PACIENTES
Motzer RJ, et al.
Lancet Oncol.
2015;16:1473-82
Lenvatinib/everolimus
(n=51)
Lenvatinib
(n=52)
Everolimus
(n=50)
Age, median (range), years
61 (44–79)
64 (41–79)
59 (37–77)
Sex, male, %
69
75
76
ECOG PS, %
0
53
56
56
1
47
44
44
Haemoglobin, %*
>130g/L (men) or >115g/L (women)
35
31
38
≤130g/L (men) or ≤115g/L (women)
65
69
62
Corrected serum calcium, %*
≥2.5mmol/L
12
15
16
<2.5mmol/L
88
85
84
MSKCC risk group, %
Favourable
24
21
24
Intermediate
37
35
38
Poor
39
44
38
Prior VEGF-targeted therapy,* %
Sunitinib
71
67
56
Pazopanib
18
25
26
Sorafenib
2
0
4
Other
10
8
14
*Lenvatinib/everolimus total sum exceeds 100% due to rounding.